Novartis acquires worldwide rights from a San Francisco biopharmaceutical firm
(Newser) -
Novartis AG will pay a San Francisco biopharmaceutical company $75 million—with the potential for an additional $500 million—for the worldwide rights to an experimental anticlotting drug the Swiss drug firm hopes will rival Plavix, reports the
Wall Street Journal. Market leader Plavix rang up $8.22 billion in...
More »
